Evidence map›Paper›PMID 37476189›Full record

ReviewJournal of Cancer2023

Involvement of FAM83 Family Proteins in the Development of Solid Tumors: An Update Review.

Yi Jiang, Jiahui Yu, Tong Zhu, Jiawen Bu, Yueting Hu, Yang Liu, Xudong Zhu, Xi Gu

Open access · goldAbstract readReview
In one paragraph

Review in Journal of Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yi JiangDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004 Liaoning province, P.R. China.
Jiahui YuDepartment of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
Tong ZhuDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004 Liaoning province, P.R. China.
Jiawen BuDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004 Liaoning province, P.R. China.
Yueting HuDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004 Liaoning province, P.R. China.
Yang LiuDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004 Liaoning province, P.R. China.
Xudong ZhuDepartment of General Surgery, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China.
Xi GuDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004 Liaoning province, P.R. China.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FAM83 family members are a group of proteins that have been implicated in various solid tumors. In this updated review, we mainly focus on the cellular localization, molecular composition, and biological function of FAM83 family proteins in solid tumors. We discussed the factors that regulate abnormal protein expression and alterations in the functional activities of solid tumor cells (including non-coding microRNAs and protein modifiers) and potential mechanisms of tumorigenesis (including the MAPK, WNT, and TGF-β signaling pathways). Further, we highlighted the application of FAM83 family proteins in the diagnoses and treatment of different cancers, such as breast, lung, liver, and ovarian cancers from two aspects: molecular marker diagnosis and tumor drug resistance. We described the overexpression of

Indexed as

abnormal expressionFAM83signaling pathwaytherapeutic targettumor cells

Identifiers

PMID37476189
PMCPMC10355199
OpenAlexW4383270692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.